YD Bio (YDESW) Retained Earnings (2025 - 2026)
YD Bio's (YDESW) quarterly Retained Earnings came in at -$3.5 million in Q2 2026, up 7.96% year-over-year from -$3.3 million in Q2 2025, and up 65.45% quarter-over-quarter from -$10.2 million in Q4 2025.
Powered by 
Analysis
YD Bio (YDESW) Retained Earnings (2025 - 2026) Analysis & Trends
YD Bio (YDESW) has reported Retained Earnings for 2 consecutive years, with -$3.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Retained Earnings rose 7.96% year-over-year to -$3.5 million in Q2 2026; TTM through Jun 2026 was -$3.5 million, a 7.96% increase from a year earlier, with the FY2025 full-year figure at -$10.2 million, changed N/A from the prior year.
- Retained Earnings was -$3.5 million for Q2 2026 at YD Bio, up from -$10.2 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$3.5 million in Q2 2026 and troughed at -$10.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.05 Bn | 198.06 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 181.76 Bn | 178.58 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 132.46 Bn | 124.61 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 82.66 Bn | 74.67 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 61.56 Bn | 56.37 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 54.69 Bn | 49.56 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.46 Bn | 30.17 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 30.15 Bn | 30.15 Bn | 1.16 Mn | 5.13 Bn |
| 10 | YD Bio | 29.02 Mn | 26.36 Mn | - | -3.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.54 Mn |
| Dec 31, 2025 | -10.24 Mn |
| Jun 30, 2025 | -3.84 Mn |